Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population

British Journal of Psychiatry

Volumn 191, Issue OCT., 2007, Pages 355-356

  Hoffman, Ralph E ^a,f   Woods, Scott W ^a   Hawkins, Keith A ^a   Pittman, Brian ^a   Tohen, Mauricio ^b   Preda, Adrian ^c   Breier, Alan ^b   Glist, Jill ^a   Addington, Jean ^d   Perkins, Diana O ^e   McGlashan, Thomas H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Yale New Haven Psychiatric Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVERSION DISORDER; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; ILLUSION; NOISE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SPECTRUM; SPEECH;

DELUSIONS; DISEASE PROGRESSION; HUMANS; NEUROPSYCHOLOGICAL TESTS; NOISE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SPEECH PERCEPTION;

EID: 35048836617     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.106.031195     Document Type: Article

References (7)

1. Andreasen, N. C. (1987) Comprehensive Assessment of Symptoms and History (CASH). University of Iowa.
2. Correll, C. U., Lencz, T., Smith, C. W., et al (2005) Prospective study of adolescents with subsyndromal psychosis: characteristics and outcome. Journal of Child and Adolescent Psychopharmacology, 15, 418-433.
3. Hoffman, R. E., Rapaport, J., Mazure, C. M., et al (1999) Schizophrenic patients reporting hallucinated 'voices' demonstrate selective speech perception alterations. American Journal of Psychiatry, 156, 393-399.
4. Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
5. McGlashan, T. H., Zipursky, R. B., Perkins, D., et al (2006) The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: efficacy and safety results of one year of treatment and one year of no-treatment follow-up. American Journal of Psychiatry, 163, 790-799.
6. McGorry, P. D., Yung, A. R., Phillips, L. J., et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921-928.
7. Nasar, S. (1998) A Beautiful Mind, p. 241. Simon & Schuster.